CRL:NYSECharles River Laboratories International, Inc. Analysis

Charles River Laboratories is trading above its 20‑day SMA (≈221) with the 20‑day, 50‑day and 200‑day averages in a bullish order, while the RSI sits at a neutral‑to‑bullish 55.6. However, the MACD histogram is negative and the MACD signal is flagged bearish, and volume has been trending down, suggesting short‑term momentum may be softening. The stock’s beta of ~1.35 and 30‑day volatility near 40% point to higher market‑related risk, and the Fear & Greed Index shows the market is in an "Extreme Greed" phase.
Fundamentally, CRL posted a loss this year (trailing EPS –3.63) but the forward EPS is projected at 12.33, giving a forward P/E of 17.8—well below the industry average of 28.7. The balance sheet is leveraged (debt‑to‑equity >100%) and cash is modest, yet analysts (15) rate the stock as a Buy with a median target of $235, implying modest upside (~5%). A new collaboration with Eli Lilly’s TuneLab AI platform could accelerate growth in AI‑enabled preclinical services, adding a compelling catalyst.